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A B S T R A C T
Purpose
Primary testicular lymphoma (PTL) has poor prognosis with failures in contralateral testis, CNS,
and extranodal sites. To prevent these events, we designed an international phase II trial
(International Extranodal Lymphoma Study Group 10 [IELSG-10]) that addressed feasibility and
activity of conventional chemoimmunotherapy associated with CNS prophylaxis and contralateral
testis irradiation. The trial was conducted by the IELSG and the Italian Lymphoma Foundation.
Patients and Methods
Fifty-three patients (age 22 to 79 years) with untreated stage I or II PTL were treated with six to
eight courses of rituximab added to cyclophosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP) every 21 days (R-CHOP21); four doses of intrathecal methotrexate (IT-MTX) and
radiotherapy (RT) to the contralateral testis (30 Gy) for all patients and to regional lymph nodes (30
to 36 Gy) for stage II disease.
Results
All patients received R-CHOP21, 50 received CNS prophylaxis, and 47 received testicular RT. With
a median follow-up of 65 months, 5-year progression-free survival and overall survival rates were
74% (95% CI, 59% to 84%) and 85% (95% CI, 71% to 92%), respectively. Ten patients relapsed
or progressed: two in lymph nodes, five in extranodal organs, and three in the CNS. The 5-year
cumulative incidence of CNS relapse was 6% (95% CI, 0% to 12%). No contralateral testis
relapses occurred. Ten patients died: lymphoma (n  6), secondary leukemia (n  2), heart failure
(n  1), and gastric cancer (n  1). Grade 3 to 4 toxicities were neutropenia, 28%; infections, 4%;
and neurologic, 13%. No deaths occurred as a result of toxicity.
Conclusion
This international prospective trial shows that combined treatment with R-CHOP21, IT-MTX, and
testicular RT was associated with a good outcome in patients with PTL. RT avoided contralateral
testis relapses, but CNS prophylaxis deserves further investigation.
J Clin Oncol 29:2766-2772. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Primary testicular non-Hodgkin’s lymphoma (PTL) is
an uncommon disease and accounts for less than 5%
of testicular malignancies and 1% to 2% of non-
Hodgkin’s lymphomas.1-5 Most patients present
with localized stages I to IIE disease; nevertheless, the
outcome is poor.1,2,6 The two largest series of PTL
reported so far are a retrospective survey of 373
patients1 by the International Extranodal Lym-
phoma Study Group (IELSG) and a US population-
based study of 769 patients in the Surveillance,
Epidemiology and End Results (SEER) database.4
Both studies showed a median overall survival (OS)
of 4 to 5 years and a continuous risk of relapse and
disease-related deaths, even 10 years after diagno-
sis.1,4 Distant relapses at extranodal sites, especially
the CNS and the contralateral testis, remain the
most therapeutic challenges in PTL, even in patients
who receive doxorubicin-based chemotherapy.1,6-10
Evidence from retrospective reports1,4,11,12 suggests
that radiotherapy (RT) to the contralateral testis
could reduce the risk of treatment failure at this
site. CNS relapses, in both brain parenchyma and
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meninges, remain a major problem since they are definitely more
common than in other aggressive lymphomas, and with 5- and 10-
year risks of 20% and 35%, they constitute a dismal event.1,7 Impor-
tantly, the best strategy to prevent CNS relapse remains to be defined.
The addition of rituximab to cyclophosphamide, doxorubicin,
vincristine, and prednisone every 21 days (R-CHOP21) or dose-
dense CHOP every 14 days (CHOP14) significantly improves OS
and progression-free survival (PFS) compared with CHOP alone
in either elderly or young low-risk patients with diffuse large B-cell
lymphoma (DLBCL).13-15 However, no specific data are available
for PTL patients.
Herein, we report the final result of what is, to the best of our
knowledge, the first prospective trial in PTL (IELSG-10), which ad-
dressed the safety and efficacy of a combined treatment strategy that
included R-CHOP21 and both CNS and testicular prophylaxis. This
trial was designed to prospectively evaluate the treatment recommen-
dations that could be drawn from the previous IELSG retrospective
study,1 and it provides a contribution to defining a proper treatment
for PTL.
PATIENTS AND METHODS
Study Design
The IELSG-10 trial was a multicenter phase II prospective study aimed at
evaluating the PFS of the R-CHOP21 regimen in combination with intrathecal
methotrexate (IT-MTX) and locoregional RT for the treatment of PTL. The
study was designed by the IELSG and conducted in collaboration with the
Italian Lymphoma Foundation. The protocol was approved by the institu-
tional review boards and/or ethics committees of each participating institu-
tion. The study was conducted in accordance with the Helsinki declaration. All
patients gave written informed consent.
Patient Selection and Assessment
Criteria for eligibility were previously untreated PTL with DLBCL histol-
ogy, age  18 years, and Ann Arbor stage I or II (Fig 1). Bilateral testicular
involvement at presentation was considered a single extranodal site, and those
without nodal involvement were classified as stage I. Exclusion criteria were
Eastern Cooperative Oncology Group (ECOG) performance status2, major
organ dysfunction, HIV seropositivity, malignancies within the last 5 years,
poor cardiac function (left ventricular ejection fraction  50%), and CNS
involvement at diagnosis.
Histologic diagnosis was centrally reviewed by D.N. according to the
WHO classification.16 Baseline assessment included bone marrow biopsy; full
laboratory workup; HIV serology; testicular ultrasound; chest, abdomen, and
pelvis computed tomography scans; multiple-gated acquisition scan or echo-
cardiography; and lumbar puncture with cytologic examination of the cere-
brospinal fluid.
Treatment Plan
The trial design is shown in Figure 2. All patients had diagnostic orchi-
ectomy. The treatment consisted of a standard dose of R-CHOP21, which
included 375 mg/m2 rituximab day 0 or day 1, 750 mg/m2 cyclophosphamide
day 1, 50 mg/m2 doxorubicin day 1, 1.4 mg/m2 (maximum 2 mg) vincristine
day 1, and 100 mg prednisone day 1 to 5. All patients were restaged after three
courses of R-CHOP21. Stage I patients received six courses of R-CHOP21.
Stage II patients received a total of six or eight courses of R-CHOP21 if they had
a complete response (CR) or partial response (PR) after the third course.
Chemoimmunotherapy was delivered in an outpatient setting.
All patients were planned to receive CNS prophylaxis with IT-MTX, 12
mg total dose, weekly for four times, during the first two R-CHOP21 courses.
At the end of chemoimmunotherapy, prophylactic irradiation to the con-
tralateral testis at 25 to 30 Gy was delivered to all patients. Patients with stage II
disease at diagnosis, beyond prophylactic testicular RT, received involved field
RT (IF-RT), which included the entire involved lymph node region with or
without an adjacent lymph node region. Minimum IF-RT, for patients with
limited para-aortic lymph node involvement only, includes the centimeter-
wide field; maximum IF includes the inverted Y field with para-aortic Iymph
Assessed for eligibility and assessed for phase II study treatment
(N = 53)
Received RCHOP × 3
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Fig 1. CONSORT diagram. Flow of the 53
patients enrolled onto the International Ex-
tranodal Lymphoma Study Group 10
(IELSG-10) study. (*) Details on radiotherapy
(RT) are reported in section on feasibility. In
stage II patients, 11 received prophylactic
testicular RT and nine received retroperito-
neal lymph-node RT. CR, complete re-
sponse; IF-RT, involved field radiotherapy;
IT-Mtx, intrathecal methotrexate; IV, intrave-
nous; PR, partial response; RCHOP, ritux-
imab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone.
Primary Testicular Lymphoma: R-CHOP With IT-MTX and Testis RT
www.jco.org © 2011 by American Society of Clinical Oncology 2767
2016 from 130.192.216.207
Information downloaded from jco.ascopubs.org and provided by at Bibl.Centralizzata medicina e chirurgia on October 4,
Copyright © 2011 American Society of Clinical Oncology. All rights reserved.
node region and bilateral pelvic lymph nodes. Patients in CR after
R-CHOP21 received IF-RT at 30 to 35 Gy; IF-RT at 35 to 45 Gy was
administered to those in CR unconfirmed (CRu) or in PR at the end of the
chemoimmunotherapy program.
Response Evaluation
Intermediate response was assessed after the third course of R-CHOP21,
and final response was evaluated after the end of chemoimmunotherapy and
RT. CR, CRu and PR were defined according to Cheson’s 1999 criteria.17 No
response was defined as any response less than a PR, progressive disease, or
death during the treatment period.
Sample Size and Study End Points
According to the evidence available when the study was planned, the
sample size was calculated by using PFS as the primary end point. Given a
5-year PFS of 48% reported in the previous IELSG retrospective analysis on
373 unselected patients with PTL, the sample size was calculated to show an
improvement of 20% in the 5-year PFS for the new treatment policy. A
one-arm trial that included 53 patients was required to reject the null hypoth-
esis of a 5-year PFS of 50% under the alternative hypothesis that the true 5-year
PFS was 70%, with a one-sided 5% significance level and 80% power, assum-
ing a 4-year accrual and 2-year minimum follow-up.
OS, PFS, and time to progression (TTP) were calculated from the date of
diagnosis and defined according to the revised National Cancer Institute
(NCI) criteria.18 PFS includes all patients with an event defined as a progres-
sion at any time during treatment, less than a CR/CRu at the end of treatment,
relapse, or death from any cause. OS includes all patients, with an event
defined as the death of a patient due to any cause. TTP is defined as the time
from study entry until documented lymphoma progression or death as a
result of lymphoma.
Statistical Methods
Cumulative survival curves were generated by using the Kaplan-Meier
method.19 Estimated percent of event rates were derived from the Kaplan-
Meier estimates and reported with 95% CIs. Incidence of CNS recurrences in
the presence of death as a competing risk and incidence of lymphoma progres-
sion or death as a result of lymphoma (TTP) were estimated by using the
cumulative incidence method.20 In TTP, deaths from other causes were
treated as competing events. The follow-up was updated as of October 31,
2009. All calculations were performed by using the cmprsk package of R
software, version 2.6.0 (R Development Core Team 2007).
RESULTS
Patient Characteristics
From June 2001 to December 2006, 53 consecutive patients were
enrolled (Table 1). The median age was 64 years (range, 22 to 79 years);
40 patients had stage I and 13 had stage II disease. Four patients had
bilateral testicular involvement at diagnosis. Lactate dehydroge-
nase or 2-microglobulin levels above normal values were ob-
served in six patients.
Feasibility
Fifty-two of the 53 patients (98%) completed R-CHOP21 as
planned, and the remaining patient experienced early progression
after four courses (Fig 1). There were no major protocol deviations
regarding chemoimmunotherapy; all patients received the scheduled
number of courses according to stage and response. Prophylactic
testicular RT was performed in 47 patients (89%; 36 stage I and 11
stage II); six patients did not receive prophylactic testicular RT because
of bilateral orchiectomy at diagnosis in one, disease progression in
one, and refusal in four. In stage II patients, nine received retroperito-
neal lymph node RT. Median delivered dose of testicular RT was 30 Gy
(range, 24 to 40 Gy), and median delivered dose of IF-RT to lymph
nodes was 30 Gy (range, 23 to 45 Gy).
CNS prophylaxis was completed as planned in 50 patients (94%),
but it was discontinued in three patients because of poor tolerance
(n 2) and toxicity (n 1). These three patients received one, two,
and three IT-MTX doses, respectively.
Stage I
Stage II
RCHOP × 3*
RCHOP × 3*
R
E
S
T
A
G
I
N
G
RCHOP × 3
RCHOP × 3
CR/PR
CR
PR RCHOP × 5
Testicular RT†
Testicular RT + IF-RT†
Testicular RT + IF-RT†
Fig 2. Plan of treatment for the Interna-
tional Extranodal Lymphoma Study Group
10 (IELSG-10) study. (*) CNS prophylaxis:
12 mg intrathecal methotrexate during the
first two courses of rituximab plus cyclo-
phosphamide, doxorubicin, vincristine, and
prednisone administered every 21 days
(RCHOP21; days 1, 8, 15, 22). (†) Testicular
radiotherapy (RT): prophylactic testicular
irradiation including the contralateral tes-
tis at 25-30 Gy; involved field RT (IF-RT)
at 30-35 Gy in stage II patients in com-
plete response (CR) after RCHOP21, at
35-45 Gy in stage II patients in CR uncon-
firmed/partial response (PR) after RCHOP21.
Table 1. Clinical Characteristics
Characteristic No. of Patients %
Age, years
Median 64
Range 22-79
Ann Arbor stage
IE 40 75
IIE 13 25
Bilateral testicular involvement 4 8
Lymph node involvement 13 25
ECOG performance status
0 47 89
1 4 7
2 2 4
B symptoms 2 4
Elevated LDH serum level 6 12
Elevated 2-microglobulin serum level† 6 14
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lac-
tate dehydrogenase.
Assessed in 50 patients; three missing.
†Assessed in 42 patients; 11 missing.
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Response and Outcome
Fifty-two patients (98%) achieved a CR, and only one experi-
enced progressive disease at nodal and extranodal sites during treat-
ment and died. At a median follow-up of 65 months, nine patients
experienced relapse. Relapses involved lymph node alone in two pa-
tients, extranodal organs (pleura, skin, unknown) with or without
lymph nodes in four patients, and CNS in three patients. Five of these
patients died of lymphoma and four are currently alive in second
remission after salvage therapy. Overall, treatment failures were ob-
served in nine of 40 patients with stage I disease and in one of 13
patients with stage II disease. This last patient had both extranodal and
nodal relapse involving pleura and retroperitoneal lymph nodes
within the RT field (actual delivered dose, 38 Gy).
With a median follow-up of 65 months, the 5-year PFS was 74%
(95% CI, 59% to 84%; Fig 3A). CNS relapses occurred in three pa-
tients: two of them had isolated CNS relapses (one meningeal and one
brain parenchymal disease) and one had a concurrent meningeal and
lymph nodal relapse. The two patients with isolated CNS relapse
received prophylactic IT-MTX as planned by the protocol; the third
patient received only two IT-MTX doses because of poor tolerance.
The 5-year cumulative incidence of CNS relapse, taking into account
the competitive risk of death, was 6% (95% CI, 0% to 12%; Fig 4). No
contralateral testis relapses were observed.
The 5-year OS rate was 85% (95% CI, 71% to 92%; Fig 3B). Ten
patients died: six of progressive disease, two of acute myelogenous
leukemia after 21 and 60 months off therapy, one of heart failure, and
one of gastric cancer after 17 and 9 months of follow-up. Overall, one
patient progressed and nine relapsed, so the 5-year cumulative inci-
dence of lymphoma progression or death as a result of lymphoma
(TTP) was 18% (95% CI, 7% to 29%; Fig 3C).
Toxicity and Safety
Hematologic toxicity was mild during the R-CHOP21 treatment.
According to the WHO toxicity criteria, a grade  3 hematologic
toxicity for neutrophils was recorded in 14 patients (26%), platelets in
four (8%), and hemoglobin in two (4%). Grade 3 nonhematologic
toxicities were reported in 13 patients (Table 2). Grade3 neurologic
toxicity was observed in seven patients (13%): two had sensory neu-
ropathy and one had motor neuropathy due to vincristine; four
patients had severe headache after IT-MTX of whom one had a cere-
brospinal fluid leak and one a subdural hematoma. CNS prophylaxis
was interrupted in three of them. Severe infections were reported
in only two patients (4%): one patient had a staphylococcus sepsis
after the third course of R-CHOP21, and one had a bacterial
pneumonia after the fourth course of R-CHOP21 and stopped
chemotherapy while in disease progression. No deaths as a result of
toxicity occurred during treatment. Fatal late adverse events, pos-
sibly associated with the treatment, occurred in three patients
(6%): two acute myelogenous leukemia and one heart failure (see
causes of death in Table 3).
DISCUSSION
The IELSG-10 study is, to the best of our knowledge, the first world-
wide prospective trial on PTL. This trial showed, in a cohort of patients
with a prolonged follow-up, that a combined treatment with R-
CHOP21 associated with CNS and testicular prophylaxis is a promis-
ing approach for PTL. This strategy is associated with a good outcome
with 5-year PFS, OS, and cumulative incidence of TTP of 74%, 85%,
and 18%, respectively. An effective systemic control of the disease with
no contralateral testis relapses and a low incidence of CNS relapse was
achieved in this trial. The acceptable toxicity profile of this treatment is
remarkable considering that, as usual for PTL, half the patients were
older than age 65 years.
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Fig 3. (A) Progression-free survival (PFS), (B) overall survival (OS), and (C)
cumulative incidence of time to progression (TTP, solid gold line; cumulative
mortality without progression, dashed blue line); 5-year PFS, 74% (95% CI, 59%
to 84%); 5-year OS, 85% (95% CI, 71% to 92%); and 5-year TTP, 18% (95% CI,
7% to 29%). Vertical bars represent 95% CIs.
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One limitation to our study should be noted. This is a phase II
trial that includes a relatively small consecutive series of patients
with PTL. Conversely, in a rare disease such as PTL, implementing
a randomized phase III trial to make strong and definitive conclu-
sions on efficacy is a complex issue, often unfeasible. Moreover, the
lack of previous prospective studies on PTL led us to use, as best
available reference, the 5-year PFS of a historical group of patients,
which was not completely comparable with the group of patients
enrolled on this phase II study. Thus, such a comparison should be
viewed with caution.
A pattern of continuous relapses and disease-related deaths was
shown in several studies in PTL series in localized stages.3,4,21,22 In the
previous IELSG retrospective study,1 the PFS progressively declined at
5 and 10 years, from 48% to 33%, respectively, in the whole series, and
from 54% to 36% in the subset of stage I patients. A similar behavior
was also observed in a recent population-based retrospective study4
with a 5- and 10-year disease-specific survival of 62% and 50%, re-
spectively (PFS was not reported). Indeed, we observed four late
lymphoma-unrelated deaths in relapse-free patients.
Notably, five of ten relapses were late events ( 2 years from the
end of therapy), which is uncommon in most nodal and extranodal
forms of DLBCL.23 This peculiar behavior of PTL underlines the
necessity of prolonged follow-up in these patients. Accordingly, the
median follow-up of this trial, which exceeds 5 years, may be not long
enough to detect all of the events.
Our treatment included three components: prophylactic RT to
the contralateral testis, addition of rituximab to CHOP, and CNS
prophylaxis. In the previous retrospective IELSG study,1 prophylactic
RT to the contralateral testis appeared to prevent testicular relapses,
which were reduced to 8% compared with 35% in those not irradi-
ated. Positive effect of prophylactic RT to the contralateral testis in this
trial further supports the inclusion of this strategy into international
clinical recommendations for PTL.24 In this study, the small number
of patients with stage II disease precluded proper assessment of the
role of adding RT to retroperitoneal lymph nodes. Indeed, the role of
RT after R-CHOP is still controversial in nodal DLBCL.25
The addition of rituximab to CHOP chemotherapy may have
improved outcome by preventing relapses with better control of mi-
croscopic systemic disease that might have been present since the
onset of the disease. The benefit of the addition of rituximab in the
treatment of PTL was recently questioned by the population-based
retrospective study, which showed no difference in the outcome of
patients with PTL treated before and after the rituximab era, using the
year 2000 as the cut point.4 However, this retrospective study was
limited by the lack of information regarding treatment delivered and
what proportion of patients actually received rituximab-containing
chemotherapy regimens. Although only randomized clinical trials can
address the impact of rituximab in PTL, these studies are difficult to
perform because of the rarity of this disease. Many studies of
patients with predominantly nodal DLBCL have provided strong
evidence of the benefit of the addition of rituximab to chemother-
apy in DLBCL, which could be an indirect proof of a potential
benefit also in PTL.13-15,26 Importantly, there is discordant published
evidence on the role of rituximab in preventing CNS relapses in
DLBCL. CNS recurrence rate was similar in 399 elderly DLBCL pa-
tients treated with R-CHOP or CHOP.27 Conversely, the analysis
of CNS events in 1,222 elderly DLBCL patients treated in the
RICOVER-60 trial showed that the addition of rituximab to CHOP14
is associated with a reduction of the relative risk of CNS disease to
0.58.28 Although this question remains open, it is likely that a better
systemic disease control in DLBCL patients treated with R-CHOP
might also result in a reduced risk of CNS recurrences.
A retrospective series of 24 patients with PTL, treated before the
rituximab era with a similar trimodality strategy (doxorubicin-based
chemotherapy, testicular RT, and IT-MTX) has shown a 5-year PFS
Table 3. Late Possible Treatment-Associated Adverse Toxicities
Late Toxicity
No. of
Patients
Age
(years)
Time From
End of
Treatment
(months) Outcome
AML 1 69 21 Death
Myelodysplasia with AML 1 79 44 Death
Heart failure 1 75 17 Death
Abbreviation: AML, acute myelogenous leukemia.
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Fig 4. Cumulative incidence of CNS recurrence (solid gold line) and cumula-
tive mortality without CNS involvement (dashed blue line); 5-year CNS
cumulative incidence, 5.9% (95% CI, 0% to 12%). Vertical bar represents
95% CI.
Table 2. Summary of Acute Hematologic and Nonhematologic Toxicities
Acute Toxicity
Grade
0 1-2 3-4
No. % No. % No. %
Hematologic, total 36 68 2 4 5 28
Anemia 48 90 3 6 2 4
Neutropenia 38 72 1 2 14 26
Thrombocytopenia 49 92 0 4 8
Neurologic 39 74 7 13 7 13
Cardiac 50 94 2 4 1 2
GI 42 79 10 19 1 2
Infection 48 90 3 6 2 4
Fever of unknown origin 50 94 2 4 1 2
Cutaneous 49 92 3 6 1 2
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and OS of 78% and 66%, respectively, but both without an apparent
curve plateau. Moreover, the risk of CNS relapse was still high
(16%).29,30 A comparison of these results with those of the IELSG-10
study may suggest that there could be some benefit from the addition
of rituximab. However, a longer follow-up is needed to clarify the role
of rituximab in PTL treatment.
The incidence of CNS relapses in both brain parenchyma and
meninges is more common in PTL than in other aggressive lympho-
mas. This complication is usually observed during the first 2 years of
follow-up in nodal DLBCL,31 whereas late CNS relapses have been
reported in PTL.1,6-10 In the previous IELSG series, 5- and 10-year risks
of CNS relapse of 20% and 35% were observed.1 In this study, the
cumulative incidence of CNS relapse at 5 years was only 6%. However,
in the absence of a comparison group without CNS prophylaxis, we
cannot ascribe these results to the introduction of CNS prophylaxis.
The best strategy for preventing CNS relapse is still a matter of debate.
The value of prophylactic intrathecal chemotherapy is controversial
because CNS relapses occur more frequently in brain parenchyma
than in meninges and also in patients who have received intrathecal
chemotherapy.9,14,16 However, PTL patients are usually elderly and
many of them may not tolerate aggressive CNS prophylaxis such as
systemic high-dose methotrexate or cytarabine chemotherapy regi-
mens. The CNS prophylaxis chosen in our study—four doses of IT-
MTX—is easy to administer with good compliance and low toxicity
despite the advanced age of the patients, and it was feasible in 94% of
the patients. Nevertheless, in our study, despite CNS prophylaxis,
three patients experienced CNS disease, and one of them had paren-
chymal disease. This underlines the necessity of further studies to
properly define the best strategy for CNS prophylaxis in patients with
PTL. For instance, the use of drugs with a higher CNS bioavailability,
such as intrathecal liposomal cytarabine and/or the addition of sys-
temic intermediate-dose methotrexate, may play a role in preventing
CNS relapses. A new prospective study (IELSG-30) conducted by the
IELSG is ongoing to test this hypothesis.
In conclusion, this study showed that R-CHOP21 combined
with CNS and testicular prophylaxis is feasible in patients younger
than age 80 years with PTL. However, the long-term benefit of this
strategy should be confirmed with a longer follow-up in a larger series
of patients. The results of this study might be considered as a reference
for future studies on this rare lymphoma.
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